2月4日,AI+可编程药物公司Generate:Biomedicines向美国证券交易委员会(SEC)正式递交招股书,计划筹集1亿美元。作为AI制药领域的明星公司,Generate累计融资高达7亿美元,获得顶级风投和跨国药企的重金押注。2025年12月,公司宣布其研发的抗TSLP长效抗体GB-0895,成为全球首个进入Ⅲ期临床的AI设计抗体。不仅如此,GB-0895展现出了惊人的研究速度,从分子...
Source Link2月4日,AI+可编程药物公司Generate:Biomedicines向美国证券交易委员会(SEC)正式递交招股书,计划筹集1亿美元。作为AI制药领域的明星公司,Generate累计融资高达7亿美元,获得顶级风投和跨国药企的重金押注。2025年12月,公司宣布其研发的抗TSLP长效抗体GB-0895,成为全球首个进入Ⅲ期临床的AI设计抗体。不仅如此,GB-0895展现出了惊人的研究速度,从分子...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.